Published in final edited form as:

Neurosci Lett. 2015 August 5; 601: 46–53. doi:10.1016/j.neulet.2014.11.042.

Dendritic Spine Alterations in Schizophrenia

Caitlin E. Moyer^a, Micah A. Shelton^a, and Robert A. Sweet^{a,b,c}

Robert A. Sweet: sweetra@upmc.edu

^aTranslational Neuroscience Program, Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, 15213 USA

^bDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213 USA

^cVISN 4 Mental Illness Research, Education and Clinical Center (MIRECC), VA Pittsburgh Healthcare System, Pittsburgh, PA, 15206 USA

Abstract

Schizophrenia is a chronic illness affecting approximately 0.5–1% of the world's population. The etiology of schizophrenia is complex, including multiple genes and contributing environmental effects that adversely impact neurodevelopment. Nevertheless, a final common result, present in many subjects with schizophrenia, is impairment of pyramidal neuron dendritic morphology in multiple regions of the cerebral cortex. In this review we summarize the evidence of reduced dendritic spine density and other dendritic abnormalities in schizophrenia, evaluate current data that informs the neurodevelopment timing of these impairments, and discuss what is known about possible upstream sources of dendritic spine loss in this illness.

Keywords

schizophrenia; dendritic spine; postmortem; adolescence; MAP2; Kalirin

Introduction

Schizophrenia is a chronic illness associated with lifelong debilitation and reduced quality of life that affects approximately 0.5–1% of the world's population [1]. Schizophrenia is characterized by a variety of symptoms, which can be categorized into positive, negative, and cognitive symptom domains [2;3]. Positive, or psychotic, symptoms describe the presence of perceptions or behaviors involving distortions of reality, including disorganized thought processes, delusions, and hallucinations. Hallucinations may occur in any sensory modality, but are typically auditory and verbal in nature. Negative symptoms refer to the absence of behaviors which should be present, including alogia (absence of speech), avolition (absence of motivation), anhedonia (inability to experience pleasure), and flattened

Correspondence to: Robert A. Sweet, sweetra@upmc.edu.

Biomedical Science Tower, Rm W-1645 3811 O'Hara Street Pittsburgh, PA 15213-2593. Tel.:412-624-0064; Fax: 412-624-9910

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

affect (inability to express emotion). Cognitive symptoms include impairments in memory performance, executive function, attention, as well as poor language and reading ability [4], and impaired social cognition [5].

The age of onset of schizophrenia, defined by the first episode of psychotic symptoms, is typically during the late adolescent to early adult years; generally between 18 and 30 years of age [2]. This might lead to a view of schizophrenia as a disorder of late neurodevelopment. However, prior to the first episode of schizophrenia, there is also evidence for cognitive deficits and other abnormalities of movement and behavior, suggesting earlier time points in neurodevelopment are affected [6].

A definite cause of schizophrenia has yet to be identified. However, evidence suggests a strong role of genetics in the etiology of schizophrenia. Monozygotic twins demonstrate 45–60% concordance for schizophrenia and the estimate of heritability is about 80% [7]. A number of potential schizophrenia susceptibility genes have been identified, including both common and rare structural variants [8]. These susceptibility loci overlap with those for other disorders of neurodevelopment, including intellectual disability and autism [9]. Importantly for attempts to model underlying mechanisms, no simple mendelian form of schizophrenia has yet to be identified [8]. The fact that the concordance rate between monozygotic twins is not 100% further suggests that environmental influences contribute to the likelihood of developing schizophrenia. Many environmental risk factors for developing schizophrenia have been identified [10], and include both early neurodevelopmental insults such as prenatal exposure to maternal infection [11] and obstetric complications [12], as well as later insults such as cannabis use in adolescence [13].

Thus, the clinical syndrome of schizophrenia is likely the result of a number of genetic contributions that interact with any of several environmental events to adversely impact the course of neurodevelopment. While this multiplicity of etiologies is daunting, it does not preclude the development of understanding of disease if there are any conserved “downstream” pathologies that could instead serve as a focus for investigation [1]. This review will focus on one such conserved neuropathology of schizophrenia, reduced dendritic spine density in neocortex. Specifically we will review the evidence of reduced dendritic spine density and other dendritic abnormalities in schizophrenia, evaluate when in neurodevelopment individuals with schizophrenia may separate from typically developing individuals on this parameter, and discuss what is known about possible upstream sources of dendritic spine loss in this illness.

Dendritic alterations in schizophrenia

Reduced dendritic spine density

Reduced density of dendritic spines is one of the most consistently observed neuropathologic alterations in postmortem brain tissue studies of individuals with schizophrenia. Dendritic spine density has been evaluated in 7 separate studies (Table 1) [14–20]. Multiple areas within frontal and temporal neocortex have been evaluated, as have primary visual cortex and the subiculum within the hippocampal formation. Significantly reduced spine density was found in schizophrenia subjects relative to control subjects in

most comparisons. In two other studies of layer 3 pyramidal neurons, one in primary visual cortex and one in prefrontal cortex, spine density was modestly reduced in schizophrenia, approaching but not reaching significance.[15;20] Only in a single study, confined to layers 5 and 6 of Brodmann Area (BA) 46, was there no reduction in spine density [16]. The median reported decrease in spine density was 23% (range 6.5%–66%). Reduced spine density has been found using Golgi-impregnated tissue to yield an estimate of density of spines per dendritic length [14;15;18;20], using antibody to label the dendritic spine protein, spinophilin [17], and using dual labeling with antibody to spinophilin and the F-actin binding toxin, phalloidin [19]. These latter, immunohistochemical approaches provide an estimate of the density of spines per volume of gray matter rather than per dendritic length. In the one study to estimate spine number, which reflects total number of spines in a region of interest independently of changes in volume of the surrounding gray matter, in deep layer 3 of primary auditory cortex reductions of 19% were found in schizophrenia [19]. Two studies evaluated whether reduced spine density in deep layer 3 of BA 46 was specific for schizophrenia. One found evidence for spine density reductions in bipolar illness, while the other found no evidence of reduction in a group consisting predominantly of major depression with psychotic features [15;20]. Finally, two studies examined whether spine density reductions might result from antipsychotic exposure in an experimental animal. In a non-human primate model a slight, but not significant, increase in spine density after more than one year of haloperidol exposure was reported [17]. In a rodent model of 28 day exposure to haloperidol or clozapine no significant effect on spine density was seen[20].

Reduced dendritic arborization

Six studies have evaluated pyramidal neuron dendrite length, field size, and/or dendrite number in schizophrenia (Table 2) [15–16;20–23]. The regions studied have included 3 prefrontal cortical areas (BA 10, BA 11, and BA 46), anterior cingulate cortex (BA 32), and primary visual cortex (BA 17). Reduced length of basilar dendrites and reduced dendritic number have been found in layer 3 in BA 10, BA 11, BA 46, and BA 32 [15;20–23]. Of note, the reduction in dendritic length found in deep layer 3 of BA 46 was also seen in groups diagnosed with other psychiatric disorders, predominantly bipolar illness and major depression with psychotic features [15;20]. In contrast, reductions in dendritic length were not found in layer 3 of primary visual cortex in schizophrenia subjects, but were seen in the subjects with other psychiatric disorders [15]. Kolluri et al., [16] found no difference in length of basal dendrites of pyramidal neurons in layer 5 and layer 6 in BA 46, but other studies found decreases in layer 5 neuron dendritic field size [21] and dendritic number [22].

Dendrite development and spine plasticity

MAP2 is located within cell bodies and dendrites, where it serves to bind, stabilize, and space microtubule bundles [24;25]. As a result, MAP2 is an important regulator of dendritic development and plasticity [26–31]. As a core constituent of the post-synaptic density in spines [32], MAP2 also binds filamentous actin [33]. Because dendritic spine plasticity depends on actin and microtubule dynamics, it is thus not surprising that spine plasticity is also effected by MAP2 [34–38].

Thus, it is notable that reduced MAP2 immunoreactivity (IR) has been reported across multiple brain regions in 6 studies of subjects with schizophrenia [19;39–43] although some conflicting reports exist [44–46] (Table 3). Reduced MAP2-IR does not correlate with common confounds such as antipsychotic exposure and postmortem interval [19;42], and is not associated with mood disorders [42]. MAP2 mRNA expression and MAP2-IR are not altered by antipsychotic exposure, although MAP2 phosphorylation is increased [19;47;48]. Because of the role of MAP2 in dendrite development and spine plasticity, reductions in MAP2-IR in schizophrenia may contribute to abnormalities in these structures observed in the neocortex of subjects with schizophrenia [19].

Neurodevelopment timeline of reduced dendritic spine density in schizophrenia

Although the onset of schizophrenia symptoms typically occurs during late adolescence or young adulthood, there are also several lines of evidence suggesting that perinatal insults contribute to schizophrenia risk [1]. As a result it has been hypothesized that reduced dendritic spine density in schizophrenia results from either a failure to elaborate normal numbers of dendritic spines in early development, or from more rapid elimination of dendritic spines in adolescent development, or both [49–51]. The findings of reduced density of dendritic spines in subjects with schizophrenia, identified in brain samples obtained at the time of death (i.e. typically in midlife or later) cannot distinguish between these hypotheses. However, other, albeit indirect, lines of evidence suggest that greater adolescent dendritic spine elimination is the more likely source of the deficit in schizophrenia.

The understanding of normative human gray matter development has been recently informed by longitudinal studies using MRI to assess gray matter density in normally developing children, adolescents, and young adults. Throughout the late teen years and early twenties, certain brain regions continue to mature via the refinement of synaptic connections and myelination of fiber tracts [52]. In humans, prefrontal and superior temporal cortices are among the last brain regions to mature, and their development is not complete until the third decade of life [53;54]. Protracted maturation in these regions may leave them vulnerable to disruptive insults during development, and in support of this, these cortical regions are heavily implicated in the neuropathology of schizophrenia, including the presence of dendritic spine reductions described above.

Imaging studies of ultra-high risk adolescent subjects transitioning to schizophrenia reveal an accelerated gray matter volume reduction in prefrontal cortex in comparison to the gray matter volume reductions seen in ultra-high risk subjects who do not develop psychosis [55]. Similarly, individuals experiencing their first psychotic episode, and ultra-high risk individuals who later develop psychosis show accelerated reductions in superior temporal gyrus gray matter volume that correlate with severity of delusions [56]. Together with other findings, the emerging picture is one in which gray matter volume deficits are not prominent at the end of childhood development in those individuals who will later develop schizophrenia. Instead, these deficits result from the concurrent acceleration of normal adolescent volume reductions and onset of schizophrenia symptoms [55].

A key adolescent neurodevelopmental process is the net loss, “pruning” of synapses in the cortex, where synapse density peaks prior to adolescence, then declines during adolescence before reaching stable adult levels [57–60]. Excitatory synapses onto dendritic spines, especially within layer 3, undergo the most dramatic elimination during the adolescent developmental period [57;61]. Thus, reductions in layer 3 dendritic spines are presumed to contribute at least a portion of the normal adolescent gray matter volume reductions observed in longitudinal imaging studies [55]. By extension, a likely interpretation of the imaging findings of accelerated adolescent gray matter reduction in schizophrenia subjects, in combination with the post-mortem tissue observations of reduced spine density in schizophrenia subjects is that processes that increase net elimination of dendritic spines contribute to the early disease course in subjects with schizophrenia. An important corollary of this interpretation would be that interventions at or around the time of transition to syndromal psychosis may be able to prevent the progression of spine loss.

Possible causes of dendritic spine loss in schizophrenia

The recent advent of two-photon in vivo imaging has contributed substantially to the understanding of the age-dependent formation and elimination of dendritic spines. These studies have demonstrated that dendritic spines are dynamic, not fixed, structures. At all ages studied some proportion of spines are generated, some remain stable, and some retract. These proportions depend on the cortical region and laminar location of the neurons studied, as well as the age and sensory experience of the animal [62]. However, in keeping with observations of total spine numbers, net spine gain outpaces spine elimination until adolescence, at which point elimination predominates until a period of equilibrium without net changes in spine numbers is reached and persists for most of adulthood [62]. Thus, a compelling hypothesis for the lower dendritic spine density in subjects with schizophrenia is that there is a shift in the molecular factors underlying this balance, leading to a greater net elimination of spines during adolescence.

One critical process underlying spine enlargement and stabilization, or conversely shrinkage and retraction, is the stabilization or destabilization, respectively, of F-actin [63]. Many mediators of the regulation of this process within dendritic spines are known, although the signaling cascades are complex and overlapping [64–66]. Nevertheless, this has led to several tests to determine whether expression of molecules that promote F-actin stabilization, spine growth, and spine stabilization is reduced in the cortex of individuals with schizophrenia. Conversely, some tests of whether expression of molecules that promote F-actin destabilization, spine retraction, and spine elimination are increased in schizophrenia have also been reported.

Hill et al. [67] examined mRNA expression of kalirin-7, Cdc42, RhoA, Rac1, and drebrin in dorsolateral prefrontal cortex of subjects with schizophrenia. All showed reduced expression, but only kalirin-7 and Cdc42 remained significantly decreased when corrected for multiple comparisons. The expression levels of Cdc42, which has been shown to promote dendritic spine outgrowth [68], and kalirin-7, which promotes spine outgrowth and mediates long term potentiation-induced spine growth [69], were each correlated with prior spine density measurements in the same subjects. However, prior observations of spine

reductions in these subjects were selective for layer 3, whereas kalirin-7 and Cdc42 mRNA reductions were not limited to this cortical layer; suggesting that reduced expression of spine growth mediators is necessary, but not sufficient, for reducing spine density. In a follow-up study examining the Cdc42 signaling pathway in greater detail, only a trend toward reduced Cdc42 mRNA expression was found, but increased mRNA expression of the layer 2–3 selective Cdc42 effector protein 3 (Cdc42EP3) was detected [70]. Importantly, expression of Cdc42, kalirin-7, and Cdc42EP3 mRNAs was not altered in monkeys exposed long term to antipsychotic medications [67;70].

Subsequently, Rubio et al. assessed protein levels of kalirin-7, Cdc42, PAK1 (a downstream target of Cdc42 and Rac1) and phospho-PAK1 in dorsolateral prefrontal cortex and anterior cingulate cortex of schizophrenia and control subjects [71]. They found reduced kalirin-7 levels in schizophrenia subjects in both regions. In contrast, levels of Cdc42 were only decreased in anterior cingulate cortex. Examination of PAK1 revealed increased total levels in dorsolateral prefrontal cortex, but reductions in PAK1 phosphorylated at threonine 423 in both regions. The reductions in phosphorylated PAK1 were not associated with alterations in downstream signaling that would reduce F-actin stability via the LIMK1-cofilin pathway, as assessed by levels of total and phosphorylated LIMK1 and cofilin in these subjects. Somewhat counter-intuitively, however, in anterior cingulate cortex Rubio et al. detected increased levels of phosphorylated myosin light chain [71], an alteration likely to promote dendritic spine F-actin stabilization [72]. Finally, Rubio et al. noted that chronic exposure to haloperidol in rats did not recapitulate any of the observed changes in protein levels [71]. These findings provide support for the hypothesis that signaling to the actin cytoskeleton may be altered in schizophrenia, an interpretation further supported by genetic evidence that copy number variations affecting the PAK1 paralogues, PAK2 [73] and PAK7 [74], are associated with schizophrenia risk. Similarly a recent report identified a rare coding variant in the KALRN gene, located in the catalytic domain of kalirin-7, in a schizophrenia patient and his sibling with major depressive disorder. *In vitro* expression of mutated kalirin-7 had reduced ability to catalyse the activation of Rac1 and did not cause the increases in spine size and density induced by expression of wild type kalirin-7. Of interest, both humans carrying the mutation demonstrated reductions in volume of superior temporal sulcus cortex, a region implicated in schizophrenia, while mice with reduced kalirin expression had reduced volume in the homologous region[75].

However, the findings of Rubio et al. also highlight the difficulty in predicting a clear outcome resulting from a reduction in any given effector due to the multiple converging and diverging pathways regulating dendritic spine actin dynamics [71]. This latter principal was further highlighted by the observation that the effect of global knockout of kalirin isoforms on dendritic spine loss varies by cortical region and developmental age, presumably reflecting age and regional variation in the background of molecules signaling to the actin cytoskeleton [76;77]. Perhaps not surprisingly, then, when Deo et al. evaluated protein levels of 4 kalirin isoforms, kalirin-5, -7, -9, and -12 in primary auditory cortex, a region in which dendritic spine loss has also been found in schizophrenia [78;79], levels of kalirin-7 were not altered in the schizophrenia subjects. Whether the differences in findings for kalirin-7 protein between Deo et al. [78] and Rubio et al. [71] result from regional variations

in disease-related effects must at present await further attempted replications, as differences in the cohorts studied is also a plausible source of the discrepancy.

Deo et al, did, however, find increased levels of kalirin-9 in the auditory cortex of schizophrenia subjects. Although the magnitude of the increase was modest, it was present in 20/26 (77%) subject pairs evaluated. In contrast, total levels of kalirin-5, kalirin-12, and PAK1 were not affected [78;79]. Finding altered kalirin-9 in schizophrenia is supported by prior reports that rare missense mutations located within the region of the *KALRN* gene shared only by kalirin-9 and -12 have been associated with risk for schizophrenia [80]. Deo et al. further evaluated the effects of sustained (2 week) over-expression of kalirin-9 in mature primary neuronal cultures. These studies recapitulated the reduced total dendritic length and reduced dendritic complexity seen in studies of schizophrenia, but did not cause a change in dendritic spine number [78]. In contrast, when kalirin-9 was overexpressed in immature neuronal cultures, it was associated with neurite elongation [81]. Thus, the effects of alteration in a single signaling molecule, such as kalirin-9, can also be influenced by the age-dependent molecular context in which they occur.

Spinophilin, an F-actin binding protein, is a mediator of long term depression, a mechanism that induces spine retraction and loss [82;83]. Thus, spinophilin knockout results in excess dendritic spine numbers during development [82]. Spinophilin recruits the RhoA GEF, Lfc, to spines [83] and targets protein phosphatase 1 to glutamate receptors [82] and to actin [84]. No change in spinophilin protein expression in prefrontal and auditory cortex [79;85] and both increased [86] and unchanged [87] expression of spinophilin mRNA in prefrontal cortex have been found in subjects with schizophrenia. However, because spinophilin is predominantly expressed in dendritic spines in cerebral cortex [88], spine loss may mask any increase in spinophilin levels within spines when gray matter homogenates are studied. Resolution of this confound awaits study using approaches that can detect spinophilin levels within remaining dendritic spines, in essence accounting for reductions in spine number [89]

Conclusions and Future Directions

Current evidence suggests that alterations of dendritic morphology, including reduced dendritic spine density, are a common pathological feature, present in multiple brain regions in many subjects with schizophrenia. Moreover, available studies indicate that this pathology is not likely to be present solely as a result of co-morbidities associated with schizophrenia, or a result of the treatments provided for these patients. These conclusions should be tempered, however, by what are still relatively small numbers of individuals with and without disease who have been studied for these parameters.

Important future directions to follow up on these correlative observations from diseased tissue would include efforts to identify potential upstream molecular sources of these dendritic impairments and evaluate them in mechanistic models to establish causality and create opportunities for testing interventions. One approach is to identify protein changes that are conserved across large numbers of diseased individuals, possibly indicating a common pathway, i.e. one downstream of multiple genetic and environmental contributors, that generates dendritic pathology (Fig. 1). One example of this might be the observations

regarding MAP2-IR which is substantially reduced (appearing qualitatively absent) in up to 60% – 80% of individuals with schizophrenia, and which multiple lines of evidence indicate could be proximate to spine pathology. Identifying the process indexed by the loss of MAP2-IR, and establishing a mechanism linking it to spine loss would have high potential for rapid translational impact. MAP2 has substantial homology of sequence, regulation, and function with MAP tau.[24] Thus, the study of MAP2 in schizophrenia could potentially take advantage of the substantially greater knowledge of tau biology, including the rapidly emerging field of tau therapeutics.[90]

A related approach would be to identify protein changes that are conserved across large numbers of diseased individuals, but which, in some cases, are also genetically linked to disease risk. For example, increased kalirin-9 protein levels in auditory cortex were present in a majority (77%) of schizophrenia cases, and genetic evidence additionally suggests a role for kalirin-9 in disease. Rare mutations in the kalirin-9 sequence have been associated with risk for schizophrenia, possibly by altering activity of kalirin's RhoA GDP/GTP exchange factor function.[80] Using this approach, it would be possible to model both common disease related increases in kalirin-9 levels and rare disease-associated kalirin mutations, providing the potential to reveal both proximate and early causal steps in pathogenesis. Because most evidence suggests that cortical gray matter volume reductions within individuals with schizophrenia emerge as an acceleration of the normal developmental trajectory during adolescence and early adulthood, the assessment of such models should evaluate this developmental phase closely.

Finally, additional efforts are necessary to understand the larger network of changes in dendritic spine proteins linked to spine loss in disease. Because post-synaptic glutamate signaling reflects the coordinated activity of many proteins, [66] understanding the genesis of altered spine density can benefit from concurrent analysis of the components and structure of this larger network.[91] Recently, the emergence of quantitative proteomics approaches suitable for the study of synaptic proteins in postmortem human tissue has enabled this approach.[92;93] Analysis of protein networks within dendritic spines has the potential to reveal unanticipated evidence of pathologic or compensatory processes, such as increased co-expression of proteins involved in glutamate signaling to the cytoskeleton in those individuals with dendritic spine reductions.[94] In addition, because most current medications target proteins, study of the larger protein network has high potential for translation into potential drug-able targets. This potential can be enhanced by combining such approaches with bioinformatic analyses in which known cellular compartments, functional pathways, and pharmacologic targets can be overlaid on the network structure to generate hypotheses regarding potential interventions to reverse or prevent spine loss.

Acknowledgments

This work was supported in part by National Institutes of Health grants MH071533, MH103204, and 5T32NS007433. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government.

Reference List

1. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. *Journal of Clinical Investigation*. 2009; 119:706–716. [PubMed: 19339762]
2. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. *Schizophr Res*. 2009; 110:1–23. [PubMed: 19328655]
3. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. *Schizophr Res*. 2008; 102:1–18. [PubMed: 18514488]
4. Salisbury DF. Semantic activation and verbal working memory maintenance in schizophrenic thought disorder: insights from electrophysiology and lexical ambiguity. *Clin EEG Neurosci*. 2008; 39:103–107. [PubMed: 18450179]
5. Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, Kring AM, Park S, Silverstein SM, Heinssen R. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. *Schizophr Bull*. 2008; 34:1211–1220. [PubMed: 18184635]
6. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. *Mol Psychiatry*. 2005; 10:434–449. [PubMed: 15700048]
7. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 2003; 60:1187–1192. [PubMed: 14662550]
8. Giusti-Rodriguez P, Sullivan PF. The genomics of schizophrenia: update and implications. *J Clin Invest*. 2013; 123:4557–4563. [PubMed: 24177465]
9. Smoller JW, Ripke S, Lee SH. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet*. 2013; 381:1371–1379. [PubMed: 23453885]
10. Brown AS. The environment and susceptibility to schizophrenia. *Prog Neurobiol*. 2011; 93:23–58. [PubMed: 20955757]
11. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. *Am J Psychiatry*. 2010; 167:261–280. [PubMed: 20123911]
12. Cannon TD, van Erp TG, Bearden CE, Loewy R, Thompson P, Toga AW, Huttunen MO, Keshavan MS, Seidman LJ, Tsuang MT. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. *Schizophr Bull*. 2003; 29:653–669. [PubMed: 14989405]
13. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. *Addiction*. 2004; 99:425–430. [PubMed: 15049742]
14. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, Barnes TRE, Hirsch SR. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. *J Neurol Neurosurg Psychiatry*. 1998; 65:446–453. [PubMed: 9771764]
15. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry*. 2000; 57:65–73. [PubMed: 10632234]
16. Kolluri N, Sun Z, Sampson AR, Lewis DA. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. *Am J Psychiatry*. 2005; 162:1200–1202. [PubMed: 15930070]
17. Sweet RA, Henteloff RA, Zhang W, Sampson AR, Lewis DA. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. *Neuropsychopharmacology*. 2009; 34:374–389. [PubMed: 18463626]
18. Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N, Hays AP, Dwork AJ. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders. *Arch Gen Psychiatry*. 2000; 57:349–356. [PubMed: 10768696]
19. Shelton, MA.; Newman, J.; Fish, KN.; Penzes, P.; Lewis, DA.; Sweet, RA. Schizophrenia-associated alterations of microtubule-associated protein 2 in human auditory cortex. Society for Neuroscience; San Diego, CA: 2013.
20. Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal Cortical Dendritic Spine Pathology in Schizophrenia and Bipolar Disorder. *JAMA Psychiatry*. 2014

21. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V, Uranova N, Greenough WT. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. *Am J Psychiatry*. 2004; 161:742–744. [PubMed: 15056523]
22. Broadbelt K, Byne W, Jones LB. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. *Schizophr Res*. 2002; 58:75–81. [PubMed: 12363393]
23. Kalus P, Müller TJ, Zuschratter W, Senitz D. The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. *Neuroreport*. 2000; 11:3621–3625. [PubMed: 11095531]
24. Dehmelt L, Halpain S. The MAP2/Tau family of microtubule-associated proteins. *Genome Biol*. 2005; 6:204. [PubMed: 15642108]
25. Sanchez C, Diaz-Nido J, Avila J. Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. *Prog Neurobiol*. 2000; 61:133–168. [PubMed: 10704996]
26. Poplawski GH, Tranziska AK, Leshchyns'ka I, Meier ID, Streichert T, Sytnyk V, Schachner M. L1CAM increases MAP2 expression via the MAPK pathway to promote neurite outgrowth. *Mol Cell Neurosci*. 2012; 50:169–178. [PubMed: 22503709]
27. Fontaine-Lenoir V, Chambraud B, Fellous A, David S, Duchossoy Y, Baulieu EE, Robel P. Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. *Proc Natl Acad Sci U S A*. 2006; 103:4711–4716. [PubMed: 16537405]
28. Sharma N, Kress Y, Shafit-Zagardo B. Antisense MAP-2 oligonucleotides induce changes in microtubule assembly and neuritic elongation in pre-existing neurites of rat cortical neurons. *Cell Motil Cytoskeleton*. 1994; 27:234–247. [PubMed: 8020109]
29. Harada A, Teng J, Takei Y, Oguchi K, Hirokawa N. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. *J Cell Biol*. 2002; 158:541–549. [PubMed: 12163474]
30. Dehmelt L, Smart FM, Ozer RS, Halpain S. The role of microtubule-associated protein 2c in the reorganization of microtubules and lamellipodia during neurite initiation. *J Neurosci*. 2003; 23:9479–9490. [PubMed: 14573527]
31. LeClerc N, Kosik KS, Cowan N, Pienkowski TP, Baas PW. Process formation in Sf9 cells induced by the expression of a microtubule-associated protein 2C-like construct. *Proc Natl Acad Sci U S A*. 1993; 90:6223–6227. [PubMed: 8327502]
32. Yun-Hong Y, Chih-Fan C, Chia-Wei C, Yen-Chung C. A study of the spatial protein organization of the postsynaptic density isolated from porcine cerebral cortex and cerebellum. *Mol Cell Proteomics*. 2011; 10:M110. [PubMed: 21715321]
33. Selden SC, Pollard TD. Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments. *J Biol Chem*. 1983; 258:7064–7071. [PubMed: 6304075]
34. Hu X, Viesselmann C, Nam S, Merriam E, Dent EW. Activity-dependent dynamic microtubule invasion of dendritic spines. *J Neurosci*. 2008; 28:13094–13105. [PubMed: 19052200]
35. Gu J, Firestein BL, Zheng JQ. Microtubules in dendritic spine development. *J Neurosci*. 2008; 28:12120–12124. [PubMed: 19005076]
36. Kapitein LC, Yau KW, Gouveia SM, van der Zwan WA, Wulf PS, Keijzer N, Demmers J, Jaworski J, Akhmanova A, Hoogenraad CC. NMDA receptor activation suppresses microtubule growth and spine entry. *J Neurosci*. 2011; 31:8194–8209. [PubMed: 21632941]
37. Jaworski J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, Grigoriev I, Camera P, Spangler SA, Di Stefano P, Demmers J, Krugers H, Defilippi P, Akhmanova A, Hoogenraad CC. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. *Neuron*. 2009; 61:85–100. [PubMed: 19146815]
38. Mitsuyama F, Niimi G, Kato K, Hirosawa K, Mikoshiba K, Okuya M, Karagiozov K, Kato Y, Kanno T, Sanoe H, Koide T. Redistribution of microtubules in dendrites of hippocampal CA1 neurons after tetanic stimulation during long-term potentiation. *Ital J Anat Embryol*. 2008; 113:17–27. [PubMed: 18491451]
39. Arnold SE, Lee VM, Gur RE, Trojanowski JQ. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. *Proc Natl Acad Sci U S A*. 1991; 88:10850–10854. [PubMed: 1961755]

40. Jones LB, Johnson N, Byne W. Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex. *Psychiatry Res.* 2002; 114:137–148. [PubMed: 12113896]
41. Rioux L, Ruscheinsky D, Arnold SE. Microtubule-associated protein MAP2 expression in olfactory bulb in schizophrenia. *Psychiatry Res.* 2004; 128:1–7. [PubMed: 15450909]
42. Rosoklija G, Keilp JG, Toomayan G, Mancevski B, Haroutunian V, Liu D, Malespina D, Hays AP, Sadiq S, Latov N, Dwork AJ. Altered subicular MAP2 immunoreactivity in schizophrenia. *Prilozi.* 2005; 26:13–34. [PubMed: 16400226]
43. Somenarain L, Jones LB. A comparative study of MAP2 immunostaining in areas 9 and 17 in schizophrenia and Huntington chorea. *J Psychiatr Res.* 2010; 44:694–699. [PubMed: 20092829]
44. Bouras C, Kovari E, Hof PR, Riederer BM, Giannakopoulos P. Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. *Acta Neuropathol.* 2001; 102:373–379. [PubMed: 11603813]
45. Cotter D, Kerwin R, Doshi B, Martin CS, Everall IP. Alterations in hippocampal non-phosphorylated MAP2 protein expression in schizophrenia. *Brain Res.* 1997; 765:238–246. [PubMed: 9313896]
46. Cotter D, Wilson S, Roberts E, Kerwin R, Everall IP. Increased dendritic MAP2 expression in the hippocampus in schizophrenia. *Schizophr Res.* 2000; 41:313–323. [PubMed: 10708340]
47. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, Compton D, Spurlock G, Turic D, Hoogendoorn B, Kwon JM, Petersen RC, Tangalos E, Norton J, Morris JC, Bullock R, Liolitsa D, Lovestone S, Hardy J, Goate A, O'Donovan M, Williams J, Owen MJ, Jones L. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. *Hum Genet.* 2001; 109:646–652. [PubMed: 11810277]
48. Lidow MS, Song ZM, Castner SA, Allen PB, Greeengard P, Goldman-Rakic PS. Antipsychotic treatment induces alterations in dendrite-and-spine associated proteins in dopamine rich areas of the primate cerebral cortex. *Biol Psychiatry.* 2001; 49:1–12. [PubMed: 11163774]
49. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? *J Psychiatr Res.* 1982; 17:319–334. [PubMed: 7187776]
50. Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. *J Psychiatr Res.* 1994; 28:239–265. [PubMed: 7932285]
51. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. *Arch Gen Psychiatry.* 2000; 57:637–648. [PubMed: 10891034]
52. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? *Nat Rev Neurosci.* 2008; 9:947–957. [PubMed: 19002191]
53. Shaw P, Kabani NJ, Lerch JP, Eckstrand K, Lenroot R, Gogtay N, Greenstein D, Clasen L, Evans A, Rapoport JL, Giedd JN, Wise SP. Neurodevelopmental trajectories of the human cerebral cortex. *J Neurosci.* 2008; 28:3586–3594. [PubMed: 18385317]
54. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, Nugent TF, Herman DH, Clasen LS, Toga AW, Rapoport JL, Thompson PM. Dynamic mapping of human cortical development during childhood through early adulthood. *Proc Natl Acad Sci U S A.* 2004; 101:8174–8179. [PubMed: 15148381]
55. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. *Schizophr Bull.* 2011; 37:504–513. [PubMed: 21505117]
56. Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, Kawasaki Y, Phillips LJ, Velakoulis D, Pantelis C. Progressive Gray Matter Reduction of the Superior Temporal Gyrus During Transition to Psychosis. *Arch Gen Psychiatry.* 2009; 66:366–376. [PubMed: 19349306]
57. Rakic P, Bourgeois J-P, Eckenhoff MF, Zecevic N, Goldman-Rakic PS. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. *Science.* 1986; 232:232–235. [PubMed: 3952506]
58. Zecevic N, Bourgeois JP, Rakic P. Changes in synaptic density in motor cortex of rhesus monkey during fetal and postnatal life. *Brain Res Dev Brain Res.* 1989; 50:11–32. [PubMed: 2582602]
59. Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human cerebral cortex. *The Journal of Comparative Neurology.* 1997; 387:167–178. [PubMed: 9336221]

60. Glantz LA, Gilmore JH, Hamer RM, Lieberman JA, Jarskog LF. Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood. *Neuroscience*. 2007; 149:582–591. [PubMed: 17916412]
61. Bourgeois JP, Goldman-Rakic PS, Rakic P. Synaptogenesis in the prefrontal cortex of rhesus monkeys. *Cerebral Cortex*. 1994; 4:78–96. [PubMed: 8180493]
62. Chen CC, Lu J, Zuo Y. Spatiotemporal dynamics of dendritic spines in the living brain. *Front Neuroanat*. 2014; 8:28. [PubMed: 24847214]
63. Okamoto K, Nagai T, Miyawaki A, Hayashi Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. *Nat Neurosci*. 2004; 7:1104–1112. [PubMed: 15361876]
64. Matsuzaki M. Factors critical for the plasticity of dendritic spines and memory storage. *Neurosci Res*. 2007; 57:1–9. [PubMed: 17070951]
65. Negishi M, Katoh H. Rho family GTPases and dendrite plasticity. *Neuroscientist*. 2005; 11:187–191. [PubMed: 15911868]
66. Calabrese B, Wilson MS, Halpain S. Development and regulation of dendritic spine synapses. *Physiology (Bethesda)*. 2006; 21:38–47. [PubMed: 16443821]
67. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry*. 2006; 11:557–566. [PubMed: 16402129]
68. Irie F, Yamaguchi Y. EphB receptors regulate dendritic spine development via intersectin, Cdc42 and N-WASP. *Nat Neurosci*. 2002; 5:1117–1118. [PubMed: 12389031]
69. Penzes P, Johnson RC, Sattler R, Zhang X, Huganir RL, Kambampati V, Mains RE, Eipper BA. The neuronal Rho-GEF Kalirin-7 interacts with PDZ domain-containing proteins and regulates dendritic morphogenesis. *Neuron*. 2001; 29:229–242. [PubMed: 11182094]
70. Ide M, Lewis DA. Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. *Biol Psychiatry*. 2010; 68:25–32. [PubMed: 20385374]
71. Rubio MD, Haroutunian V, Meador-Woodruff JH. Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia. *Biol Psychiatry*. 2012; 71:906–914. [PubMed: 22458949]
72. Rex CS, Gavin CF, Rubio MD, Kramar EA, Chen LY, Jia Y, Huganir RL, Muzyczka N, Gall CM, Miller CA, Lynch G, Rumbaugh G. Myosin IIb regulates actin dynamics during synaptic plasticity and memory formation. *Neuron*. 2010; 67:603–617. [PubMed: 20797537]
73. Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, Sobreira NL, Valle D, Rudd MK, Satten G, Cutler DJ, Pulver AE, Warren ST. Microdeletions of 3q29 confer high risk for schizophrenia. *Am J Hum Genet*. 2010; 87:229–236. [PubMed: 20691406]
74. Morris DW, Pearson RD, Cormican P, Kenny EM, O'Dushlaine CT, Perreault LP, Giannoulitou E, Tropea D, Maher BS, Wormley B, Kelleher E, Fahey C, Molinos I, Bellini S, Pirinen M, Strange A, Freeman C, Thiselton DL, Elves RL, Regan R, Ennis S, Dinan TG, McDonald C, Murphy KC, O'Callaghan E, Waddington JL, Walsh D, O'Donovan M, Grozeva D, Craddock N, Stone J, Scolnick E, Purcell S, Sklar P, Coe B, Eichler EE, Ophoff R, Buizer J, Szatkiewicz J, Hultman C, Sullivan P, Gurling H, McQuillin A, St Clair D, Rees E, Kirov G, Walters J, Blackwood D, Johnstone M, Donohoe G, O'Neill FA, Kendler KS, Gill M, Riley BP, Spencer CC, Corvin A. An inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis. *Hum Mol Genet*. 2014; 23:3316–3326. [PubMed: 24474471]
75. Russell TA, Blizinsky KD, Cobia DJ, Cahill ME, Xie Z, Sweet RA, Duan J, Gejman PV, Wang L, Csernansky JG, Penzes P. A sequence variant in human KALRN impairs protein function and coincides with reduced cortical thickness. *Nat Commun*. 2014; 5:4858. [PubMed: 25224588]
76. Cahill ME, Xie Z, Day M, Photowala H, Barbolina MV, Miller CA, Weiss C, Radulovic J, Sweatt JD, Disterhoft JF, Surmeier DJ, Penzes P. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. *Proc Natl Acad Sci U S A*. 2009; 106:13058–13063. [PubMed: 19625617]

77. Moyer, CE.; Peet, E.; Thiels, F.; Sweet, RA. A probe of auditory cortex function in genetic models of schizophrenia: Assessment of silent gap detection thresholds across adolescence in three inbred mouse strains. Society for Neuroscience; San Diego, CA: 2012.
78. Deo AJ, Cahill ME, Li S, Goldszer I, Hentleff R, Vanleeuwen JE, Rafalovich I, Gao R, Stachowski EK, Sampson AR, Lewis DA, Penzes P, Sweet RA. Increased expression of Kalirin-9 in the auditory cortex of schizophrenia subjects: Its role in dendritic pathology 1. *Neurobiol Dis.* 2011; 45:796–803. [PubMed: 22120753]
79. Deo AJ, Goldszer IM, Li S, DiBitetto JV, Hentleff RA, Sampson AR, Lewis DA, Penzes P, Sweet RA. PAK1 Protein Expression in the Auditory Cortex of Schizophrenia Subjects. *PLoS One.* 2013; 8:e59458. [PubMed: 23613712]
80. Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T, Okochi T, Fukuo Y, Ujike H, Suzuki M, Inada T, Hashimoto R, Takeda M, Kaibuchi K, Iwata N, Ozaki N. Resequencing and Association Analysis of the KALRN and EPHB1 Genes And Their Contribution to Schizophrenia Susceptibility. *Schizophr Bull.* 2012; 38:552–560. [PubMed: 21041834]
81. Penzes P, Johnson RC, Kambampati V, Mains RE, Eipper BA. Distinct roles for the two Rho GDP/GTP exchange factor domains of kalirin in regulation of neurite growth and neuronal morphology. *J Neurosci.* 2001; 21:8426–8434. [PubMed: 11606631]
82. Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, Zhuo M, Allen PB, Ouimet CC, Greengard P. Spinophilin regulates the formation and function of dendritic spines. *Proc Natl Acad Sci U S A.* 2000; 97:9287–9292. [PubMed: 10922077]
83. Ryan XP, Alldritt J, Svenningsson P, Allen PB, Wu GY, Nairn AC, Greengard P. The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. *Neuron.* 2005; 47:85–100. [PubMed: 15996550]
84. Fernandez A, Brautigan DL, Mumby M, Lamb NJ. Protein phosphatase type-1, not type-2A modulates actin microfilament integrity and myosin light chain phosphorylation in living nonmuscle cells. *J Cell Biol.* 1990; 111:103–112. [PubMed: 2164027]
85. Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. *Arch Gen Psychiatry.* 2003; 60:311–319. [PubMed: 12622665]
86. Baracskey KL, Haroutunian V, Meador-Woodruff JH. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. *Synapse.* 2006; 60:271–279. [PubMed: 16786528]
87. Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, Herman MM, Weinberger DR, Kleinman JE. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. *Arch Gen Psychiatry.* 2004; 61:544–555. [PubMed: 15184234]
88. Muly EC, Smith Y, Allen P, Greengard P. Subcellular distribution of spinophilin immunolabeling in primate prefrontal cortex: localization to and within dendritic spines. *J Comp Neurol.* 2004; 469:185–197. [PubMed: 14694533]
89. Sweet RA, Fish KN, Lewis DA. Mapping Synaptic Pathology within Cerebral Cortical Circuits in Subjects with Schizophrenia. *Front Hum Neurosci.* 2010; 4:44. [PubMed: 20631852]
90. Yin Y, Lin L, Ruiz C, Khan S, Cameron MD, Grant W, Pocas J, Eid N, Park H, Schroter T, Lograsso PV, Feng Y. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. *J Med Chem.* 2013; 56:3568–3581. [PubMed: 23570561]
91. Gaiteri C, Sibille E. Differentially expressed genes in major depression reside on the periphery of resilient gene coexpression networks. *Front Neurosci.* 2011; 5:95. [PubMed: 21922000]
92. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. *Nat Methods.* 2013; 10:28–34. [PubMed: 23269374]
93. Macdonald ML, Ciccimaro E, Prakash A, Banerjee A, Seeholzer SH, Blair IA, Hahn CG. Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brain tissue. *Mol Cell Proteomics.* 2012; 11:1670–1681. [PubMed: 22942359]
94. Macdonald ML, Ding Y, Newman J, Yates N, Lewis DA, Sweet RA. Targeted proteomic analysis of postmortem auditory cortex reveals an altered glutamatergic signaling protein network in schizophrenia. *Biol Psychiatry.* In Press.

Highlights

Schizophrenia is a neurodevelopment disorder with multiple contributing genes

Dendritic impairments, including spine loss, are present in schizophrenia

Identification of conserved underlying molecular pathologies is ongoing

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Studies of dendritic spine density in schizophrenia

<REF>Reference	Brain regions	N of Subjects SZ/C	Method	Finding(s)
Garey et al., 1998 [14]	BA 10, BA 11, BA 45	13/11	Golgi	66% decrease in layer 3
Garey et al., 1998 [14]	BA 38, BA 20, BA 21, BA 22	13/11	Golgi	59% decrease in layer 3
Glantz and Lewis, 2000 [15]	BA 46	15/15	Golgi	23% decrease in deep layer 3. No significant reduction in superficial layer 3.
Glantz and Lewis, 2000 [15]	BA 17	13/15	Golgi	14% reduction (not significant) in layer 3
Rosoklija et al., 2000 [18]	Subiculum	13/8	Golgi	35% decrease
Kolluri et al., 2005 [16]	BA 46	14/15	Golgi	No difference in layers 5 and 6.
Sweet et al., 2009 [17]	BA 41	15/15	Anti-spinophilin antibody	27% decrease in deep layer 3
Sweet et al., 2009 [17]	BA 42	15/15	Anti-spinophilin antibody	22% decrease in deep layer 3
Shelton et al. 2013 [19]	BA 41	20/20	Dual label with anti- spinophilin antibody and phalloidin	20% decrease in spine density and spine number in deep layer 3
Konopaske et al. 2014 [20]	BA 46	14/19	Golgi	6.5% decrease in spine density and 21.6% decrease in number of spines per dendrite in deep layer 3

BA- Brodmann area; SZ- schizophrenia; C- control

Table 2

Studies of dendritic length and number in schizophrenia.

Reference	Brain region	N of Subjects	SZ/C	Method	Finding(s)
Glantz and Lewis, 2000 [15]	BA 46	15/15		Golgi	14% decrease in basilar dendrite length in deep layer 3, but not superficial layer 3, in schizophrenia
Glantz and Lewis, 2000 [15]	BA 17	13/15		Golgi	No difference in basilar dendrite length in layer 3 in schizophrenia
Kalus et al., 2000 [23]	BA 11	5/5		Golgi	29% decrease in basilar dendrite length in layer 3
Broadbent et al., 2002 [22]	BA 32	11/11		Golgi	Layer 3– 17% decrease in primary and 15% decrease in secondary dendrite numbers in schizophrenia; Layer 5– 29% decrease in primary and 46% decrease in secondary dendrite numbers in schizophrenia
Black et al., 2004 [21]	BA 10	15/18		Golgi	40% decrease in basilar dendrite field size in layer 5
Kolluri et al., 2005 [16]	BA 46	14/15		Golgi	No difference in basilar dendrite length in layers 5 or 6
Konopaske et al. 2014 [20]	BA 46	14/19		Golgi	18.3% decrease in basilar dendrite length in deep layer 3

BA- Brodmann area; SZ- schizophrenia; C- control

Table 3

Studies of microtubule-associated protein 2 immunoreactivity in schizophrenia.

Study	N of Subjects SZ/C	Region	Antibody Name	Antibody Phospho- dependence	Antibody Isoform specificity	Finding(s)
Arnold et al. 1991 [39]	6/12	Hippocampus and associated areas ^a	AP14 AP18 M12, T24, T34, T39, T42	Independent Dependent Unknown	HMW All Unknown	Decreased MAP2-IR in the subiculum of 83% of SZ subjects and entorhinal cortex of 67% of SZ subjects
Bouras et al. 2001 [44]	44/55	BA 24	AP14 AP18	Independent Dependent	HMW All	No difference in MAP2-IR using quantitative immunodot analysis
Cotter et al. 1997 [45]	8/11	Hippocampus	972 305	Independent Dependent	All All	Increase in non-phosphorylated MAP2- IR in left subiculum and left CA1 in SZ subjects
Cotter et al. 2000 [46]	12/13	Hippocampus	B9 972	Independent Independent	All All	Increase in dendritic arborization in hippocampal regions CA1, CA2, CA3, and CA4 in SZ subjects
Jones et al. 2002 [40]	7/7	BA 9 BA 32	Anti-MAP2 ^b	Unknown	Unknown	MAP2 area fraction is reduced by 40% in layer 3 and 45% in layer 5 of BA 9 in SZ subjects. MAP2 area fraction is reduced by 32% in layer 3 and 44% in layer 5 of BA 32 in SZ subjects
Rosoklija et al. 2005 [42]	64/47	Hippocampus and associated areas	Anti-MAP2	Independent	HMW	Decreased MAP2-IR in subiculum of 20% of SZ subjects
Rioux et al. 2004 [41]	11/7	Olfactory bulb	AP18 Clone C	Dependent Independent	All All	Significant reduction in MAP2-IR in SZ subjects
Somenarain et al. 2010 [43]	8/8	BA 9	Anti-MAP2	Independent	HMW	MAP2 area fraction is reduced by 39% in layer 3 and 38% in layer 5 in SZ subjects
Shelton et al., 2013 [19]	20/20	BA 41	SMI-52	Independent	All	MAP2-IR is reduced by 70% in BA41 deep layer 3. MAP2-IR below lowest value observed in any control subject in 60% of SZ subjects

^a Associated areas refers to subiculum, parahippocampal cortex, and entorhinal cortex

^b Anti-MAP2 here refers to the binding target of the antibody and is not meant to suggest that all antibodies termed anti-MAP2 are identical.

Abbreviations: BA- Brodmann area; SZ- schizophrenia; C- control; HMW- high molecular weight MAP2 isoforms (MAP2A, MAP2B); MAP2-IR- MAP2 Immunoreactivity; CA1, CA2, CA3, CA4- Cornu Ammonis areas 1–4.